Active substances
Amlodipine + Hydrochlorothiazide + Olmesartan
- SFDA 25
- US FDA 8
- US price lines 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Erastapecs Trio | 40,25,10 mg,mg,mg | Tablet · Oral use | 30 Blister | SAR 95.00 | Generic · Prescription | Apex Pharma | Valid |
| Erastapecs Trio | 40,12.5,5 mg,mg,mg | Tablet · Oral use | 30 Blister | SAR 84.85 | Generic · Prescription | Apex Pharma | Valid |
| Erastapecs Trio | 20,12.5,5 mg,mg,mg | Tablet · Oral use | 30 Blister | SAR 66.40 | Generic · Prescription | Apex Pharma | Valid |
| Olmexa Plus | 40,10,25 ,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 85.10 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa Plus | 40,5,25 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 80.20 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa Plus | 20,5,12.5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 59.10 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa Plus | 40,10,12.5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 79.70 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa Plus | 40,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 74.80 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmidip HCT | 20,5,12.5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 52.10 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| Olmidip HCT | 40,5,12.5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 66.75 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| Olmidip HCT | 40,5,25 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 66.75 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| Olmidip HCT | 40,10,12.5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 74.25 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| Olmidip HCT | 40,10,25 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 74.25 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| SEVIKAR HCT 20/5/12.5MG FILM COATED TABLET | 20,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 86.85 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVIKAR HCT 40/10/12.5MG FILM COATED TABLET | 40,12.5,10 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 124.20 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVIKAR HCT 40/10/25MG FILM COATED TABLET | 40,25,10 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 124.20 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVIKAR HCT 40/5/12.5MG FILM COATED TABLET | 40,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 110.95 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVIKAR HCT 40/5/25MG FILM COATED TABLET | 40,25,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 110.95 | NCE · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVITENSE PLUS 20/5/12.5 MG FILM COATED TABLET | 20,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Bottle | SAR 73.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| SEVITENSE PLUS 40/10/12.5 MG FILM COATED TABLET | 40,12.5,10 mg,mg,mg | Film-coated tablet · Oral use | 28 Bottle | SAR 105.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| SEVITENSE PLUS 40/10/25 MG FILM COATED TABLET | 40,25,10 mg,mg,mg | Film-coated tablet · Oral use | 28 Bottle | SAR 105.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| SEVITENSE PLUS 40/5/12.5 MG FILM COATED TABLET | 40,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Bottle | SAR 94.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| SEVITENSE PLUS 40/5/25 MG FILM COATED TABLET | 40,25,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Bottle | SAR 94.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Trioltan | 40,12.5,10 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 55.85 | Generic · Prescription | Med City Pharma | Valid |
| Trioltan | 40,12.5,5 mg,mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 49.85 | Generic · Prescription | Med City Pharma | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC KIDNEY DISEASE; HYPERTENSION
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRIBENZOR | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | COSETTE | Prescription | 23 Jul 2010 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | TORRENT | Prescription | 26 Oct 2016 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | PH HEALTH | Prescription | 26 Oct 2016 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | TEVA PHARMS USA | Prescription | 3 Nov 2016 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | PIRAMAL | Prescription | 14 May 2025 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | MACLEODS PHARMS | Prescription | 18 Jul 2025 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | HETERO LABS LTD V | Prescription | 6 Oct 2025 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | EQ 5MG BASE;12.5MG;20MG; EQ 5MG BASE;12.5MG;40MG; EQ 5MG BASE;25MG;40MG; EQ 10MG BASE;12.5MG;40MG; EQ 10MG BASE;25MG;40MG | tablet · oral | MICRO LABS | Prescription | 24 Nov 2025 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 20-5-12.5 | $0.77624 | per EA | 23 Sep 2026 |
| US NADAC | OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-12.5 | $1.15137 | per EA | 23 Sep 2026 |
| US NADAC | OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG | $0.98947 | per EA | 23 Sep 2026 |
| US NADAC | OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 | $1.01976 | per EA | 23 Sep 2026 |
| US NADAC | OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-25 MG | $0.99481 | per EA | 23 Sep 2026 |
| US NADAC | TRIBENZOR 40-10-25 MG TABLET | $19.41413 | per EA | 1 Jul 2026 |
| US NADAC | TRIBENZOR 40-5-12.5 MG TABLET | $19.53853 | per EA | 1 Jul 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.